Affinity Investment Advisors, LLC Halozyme Therapeutics, Inc. Transaction History

Affinity Investment Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$33.32 - $42.1 $227,242 - $287,122	-6,820 Reduced 43.42%	8,886 $328,000
Q3 2023 Oct 26, 2023	SELL	$36.46 - $44.03 $17,500 - $21,134	-480 Reduced 2.97%	15,706 $599,000
Q2 2023 Aug 10, 2023	SELL	$30.28 - $38.74 $89,568 - $114,592	-2,958 Reduced 15.45%	16,186 $583,000
Q4 2022 Feb 08, 2023	SELL	$40.06 - $59.44 $110,445 - $163,876	-2,757 Reduced 12.59%	19,144 $1.09 Million
Q2 2022 Jul 27, 2022	SELL	$37.35 - $48.3 $34,735 - $44,919	-930 Reduced 4.07%	21,901 $964,000
Q1 2022 May 05, 2022	SELL	$31.97 - $41.06 $21,739 - $27,920	-680 Reduced 2.89%	22,831 $911,000
Q4 2021 Feb 04, 2022	SELL	$31.82 - $40.75 $15,432 - $19,763	-485 Reduced 2.02%	23,511 $945,000
Q3 2021 Nov 08, 2021	BUY	$38.47 - $46.42 $923,126 - $1.11 Million	23,996 New	23,996 $976,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Affinity Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Investment Advisors, LLC with notifications on news.